Biomm S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was BRL 118.19 million compared to BRL 104.95 million a year ago. Net loss was BRL 81.14 million compared to BRL 92.56 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.08 BRL | -1.71% | -10.67% | +178.20% |
04-18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
04-17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
1st Jan change | Capi. | |
---|---|---|
+178.20% | 277M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.47% | 22.28B | |
-5.57% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- BIOM3 Stock
- News Biomm S.A.
- Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023